Sobi publishes Q2 2022 report
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter of 2022 April – June 2022 · Total revenue SEK 3,876 M (3,211), +21 per cent, +10 per cent at constant exchange rates (CER)1 · Haematology revenue SEK 2,688 M (2,125), +16 per cent at CER of which Elocta® SEK 1,107 M (1,005), +6 per cent at CER; Alprolix® SEK 468 M (438), +2 per cent at CER; Doptelet® SEK 618 M (230), +126 per cent at CER and Aspaveli®/Empaveli™ SEK 38 M (-) · Immunology revenue SEK 847 M (752), stable at CER of which Kineret® SEK 545 M (550),